CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Chemomab Therapeutics Ltd - ADR is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Chemomab Therapeutics Ltd - ADR
Kiryat Atidim, Building 7
Phone: +972 25486555p:+972 25486555 TEL AVIV-YAFO, 6158002  Israel Ticker: CMMBCMMB

Business Summary
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board NissimDarvish 57 6/1/2023 3/16/2021
Chief Executive Officer, Director AdiMor 41 6/1/2023 3/16/2021
Chief Financial Officer SigalFattal 51 6/1/2023 10/1/2020
4 additional Officers and Directors records available in full report.

Business Names
Business Name
ANCN
Chemomab Ltd.
Chemomab Therapeutics Israel Ltd.
Chemomab Therapeutics, Inc.
CMMB

General Information
Number of Employees: 37 (As of 12/31/2022)
Outstanding Shares: 284,094,700 (As of 12/31/2023)
Shareholders: 7
Stock Exchange: NASD
Fax Number: +972 25486550


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, March 27, 2024